245 related articles for article (PubMed ID: 24555569)
1. Activation of peripheral KCNQ channels attenuates inflammatory pain.
Hayashi H; Iwata M; Tsuchimori N; Matsumoto T
Mol Pain; 2014 Feb; 10():15. PubMed ID: 24555569
[TBL] [Abstract][Full Text] [Related]
2. Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Xu W; Wu Y; Bi Y; Tan L; Gan Y; Wang K
Mol Pain; 2010 Aug; 6():49. PubMed ID: 20796319
[TBL] [Abstract][Full Text] [Related]
3. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Dost R; Rostock A; Rundfeldt C
Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
[TBL] [Abstract][Full Text] [Related]
4. KCNQ2/3/5 channels in dorsal root ganglion neurons can be therapeutic targets of neuropathic pain in diabetic rats.
Yu T; Li L; Liu H; Li H; Liu Z; Li Z
Mol Pain; 2018; 14():1744806918793229. PubMed ID: 30027794
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
Sotty F; Damgaard T; Montezinho LP; Mørk A; Olsen CK; Bundgaard C; Husum H
J Pharmacol Exp Ther; 2009 Mar; 328(3):951-62. PubMed ID: 19098162
[TBL] [Abstract][Full Text] [Related]
6. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain.
Blackburn-Munro G; Jensen BS
Eur J Pharmacol; 2003 Jan; 460(2-3):109-16. PubMed ID: 12559370
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of A-fiber-mediated excitatory transmission underlies the analgesic effects of KCNQ channel opening in the spinal dorsal horn.
Oyama M; Watanabe S; Iwai T; Tanabe M
Neuropharmacology; 2024 Aug; 254():109994. PubMed ID: 38750803
[TBL] [Abstract][Full Text] [Related]
8. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
[TBL] [Abstract][Full Text] [Related]
9. Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury.
Wu Z; Li L; Xie F; Du J; Zuo Y; Frost JA; Carlton SM; Walters ET; Yang Q
J Neurotrauma; 2017 Mar; 34(6):1260-1270. PubMed ID: 28073317
[TBL] [Abstract][Full Text] [Related]
10. Kv7 (KCNQ) channel openers induce hypothermia in the mouse.
Kristensen LV; Sandager-Nielsen K; Hansen HH
Neurosci Lett; 2011 Jan; 488(2):178-82. PubMed ID: 21087654
[TBL] [Abstract][Full Text] [Related]
11. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
12. Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.
Zheng Q; Fang D; Liu M; Cai J; Wan Y; Han JS; Xing GG
Pain; 2013 Mar; 154(3):434-448. PubMed ID: 23352759
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
Jensen MM; Lange SC; Thomsen MS; Hansen HH; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):339-42. PubMed ID: 21599837
[TBL] [Abstract][Full Text] [Related]
14. Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain.
Cai J; Fang D; Liu XD; Li S; Ren J; Xing GG
Oncol Rep; 2015 Mar; 33(3):1540-50. PubMed ID: 25592230
[TBL] [Abstract][Full Text] [Related]
15. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice.
Hirano K; Kuratani K; Fujiyoshi M; Tashiro N; Hayashi E; Kinoshita M
Neurosci Lett; 2007 Feb; 413(2):159-62. PubMed ID: 17184917
[TBL] [Abstract][Full Text] [Related]
16. KCNQ/M currents in sensory neurons: significance for pain therapy.
Passmore GM; Selyanko AA; Mistry M; Al-Qatari M; Marsh SJ; Matthews EA; Dickenson AH; Brown TA; Burbidge SA; Main M; Brown DA
J Neurosci; 2003 Aug; 23(18):7227-36. PubMed ID: 12904483
[TBL] [Abstract][Full Text] [Related]
17. Retigabine: chemical synthesis to clinical application.
Blackburn-Munro G; Dalby-Brown W; Mirza NR; Mikkelsen JD; Blackburn-Munro RE
CNS Drug Rev; 2005; 11(1):1-20. PubMed ID: 15867950
[TBL] [Abstract][Full Text] [Related]
18. KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia.
Abd-Elsayed AA; Ikeda R; Jia Z; Ling J; Zuo X; Li M; Gu JG
Mol Pain; 2015 Jul; 11():45. PubMed ID: 26227020
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder.
Rode F; Svalø J; Sheykhzade M; Rønn LC
Eur J Pharmacol; 2010 Jul; 638(1-3):121-7. PubMed ID: 20385123
[TBL] [Abstract][Full Text] [Related]
20. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
